Background: Cerebral palsy (CP) is the most common cause of chronic motor disability in childhood. Children with CP often demonstrate various types of abnormal muscle tone, with spastic CP being the most common presentation. Spasticity and the resulting decrease in joint range of motion of lower extremities could lead to gait difficulties in this patient population. Previous research has shown that botulinum toxin (BTX) can decrease muscle spasticity and improve joint range of motion. However, it remains unclear whether BTX improves ambulation capacity in children with CP. Objective: The purpose of this systematic review (SR) was to evaluate the effects of BTX on gait in children with CP. Methods: PubMed and Embase were searched on November 18, 2021 for randomized controlled trials or quasi-experimental studies with control that investigated the effectiveness of BTX on gait in children with CP. Only studies published since 2011 were included in the current review. Risk of bias of the included studies was assessed with PEDro. Results: Seven studies with a total number of 367 individuals with spastic CP were included in this SR. The control group received conventional physical therapy, while the interventional group received single dose of BTX injection in one of the lower extremity muscle groups in addition to conventional physical therapy. Our findings revealed BTX improved gait parameters at 4-12 weeks following injection as compared to the control group (p0.05). Side effects including local muscle weakness were noted in a small portion of participants. The average PEDro score is 7.7/10, indicating good quality of the included studies. Conclusion: BTX could potentially improve ambulation capacity in children with CP.
